Ticagrelor shift from PLATO to PEGASUS: Vanished mortality benefit, excess cancer deaths, massive discontinuations, and overshooting target events

International Journal of Cardiology

Volumn 201, Issue , 2015, Pages 508-512

  Serebruany, Victor L ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Aspirin; Cancer; Clinical trial; Mortality; Sepsis; Ticagrelor

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; PLACEBO; TICAGRELOR; ADENOSINE; ANTITHROMBOCYTIC AGENT; PURINERGIC P2Y RECEPTOR ANTAGONIST; TICLOPIDINE;

ACUTE CORONARY SYNDROME; BLEEDING; CANCER MORTALITY; CANCER RISK; COMBINATION CHEMOTHERAPY; CORONARY ARTERY DISEASE; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; HEART ARRHYTHMIA; HUMAN; LOADING DRUG DOSE; LOW DRUG DOSE; MONOTHERAPY; MORTALITY; PRIORITY JOURNAL; REVIEW; SEPSIS; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; FOLLOW UP; NEOPLASMS; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ACUTE CORONARY SYNDROME; ADENOSINE; ASPIRIN; FOLLOW-UP STUDIES; HEMORRHAGE; HUMANS; MORTALITY; NEOPLASMS; PLATELET AGGREGATION INHIBITORS; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEPSIS; TICLOPIDINE;

EID: 84943538342     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2015.08.043     Document Type: Editorial

References (20)

1. S. Bansilal, M.P. Bonaca, and M.S. Sabatine Ticagrelor for acute coronary syndromes Expert. Rev. Cardiovasc. Ther. 11 2013 1473 1484
2. L. Wallentin, R.C. Becker, A. Budaj, C.P. Cannon, H. Emanuelsson, C. Held, J. Horrow, S. Husted, S. James, H. Katus, K.W. Mahaffey, B.M. Scirica, A. Skene, P.G. Steg, R.F. Storey, R.A. Harrington, PLATO Investigators, A. Freij, and M. Thorsén Ticagrelor versus clopidogrel in patients with acute coronary syndromes N. Engl. J. Med. 61 2009 1045 1057
3. V.L. Serebruany Paradoxical excess mortality in the PLATO trial should be independently verified Thromb. Haemost. 105 2011 752 759
4. J.J. DiNicolantonio, and A. Tomek Misrepresentation of vital status follow-up: challenging the integrity of the PLATO trial and the claimed mortality benefit of ticagrelor versus clopidogrel Int. J. Cardiol. 169 2013 145 146
5. G.N. Levine, Y.H. Jeong, S. Goto, J.L. Anderson, Y. Huo, J.L. Mega, K. Taubert, and S.C. Smith Jr. Expert consensus document: World Heart Federation expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI Nat. Rev. Cardiol. 11 2014 597 606
6. H. Daida, K. Miyauchi, H. Ogawa, H. Yokoi, M. Matsumoto, M. Kitakaze, T. Kimura, T. Matsubara, Y. Ikari, K. Kimura, K. Tsukahara, H. Origasa, Y. Morino, H. Tsutsui, M. Kobayashi, T. Isshiki, and PACIFIC investigators Management and two-year long-term clinical outcome of acute coronary syndrome in Japan: prevention of atherothrombotic incidents following ischemic coronary attack (PACIFIC) registry Circ. J. 77 2013 934 943
7. G. Montalescot, A.W. van't Hof, F. Lapostolle, and et al. Prehospital ticagrelor in ST-segment elevation myocardial infarction N. Engl. J. Med. 371 2014 1016 1027
8. V. Serebruany, V. Cherepanov, and A. Dukhanin Significant excess of early deaths after prehospital ticagrelor: The ATLANTIC trial challenge Thromb. Haemost. 114 2015 7 8
9. M.P. Bonaca, D.L. Bhatt, E. Braunwald, M. Cohen, P.G. Steg, R.F. Storey, P. Held, E.C. Jensen, and M.S. Sabatine Design and rationale for the Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54 (PEGASUS-TIMI 54) trial Am. Heart J. 167 2014 437 444
10. M.P. Bonaca, D.L. Bhatt, M. Cohen, P.G. Steg, R.F. Storey, E.C. Jensen, G. Magnani, S. Bansilal, M.P. Fish, K. Im, O. Bengtsson, Ophuis TO, A. Budaj, P. Theroux, M. Ruda, C. Hamm, S. Goto, J. Spinar, J.C. Nicolau, R.G. Kiss, S.A. Murphy, S.D. Wiviott, P. Held, E. Braunwald, M.S. Sabatine, and PEGASUS-TIMI 54 Steering Committee and Investigators Long-term use of ticagrelor in patients with prior myocardial infarction N. Engl. J. Med. 372 2015 1791 1800
11. A.K. Rao, C. Pratt, A. Berke, A. Jaffe, I. Ockene, T.L. Schreiber, W.R. Bell, G. Knatterud, T.L. Robertson, and M.L. Terrin Thrombolysis In Myocardial Infarction (TIMI) trial - phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase J. Am. Coll. Cardiol. 11 1988 1 11
12. R. Mehran, S.V. Rao, D.L. Bhatt, C.M. Gibson, A. Caixeta, J. Eikelboom, S. Kaul, S.D. Wiviott, V. Menon, E. Nikolsky, V. Serebruany, M. Valgimigli, P. Vranckx, D. Taggart, J.F. Sabik, D.E. Cutlip, M.W. Krucoff, E.M. Ohman, P.G. Steg, and H. White Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium Circulation 123 2011 2736 2747
13. V.L. Serebruany, and D. Atar Assessment of bleeding events in clinical trials - proposal of a new classification Am. J. Cardiol. 99 2007 288 290
14. L. Mauri, D.J. Kereiakes, R.W. Yeh, P. Driscoll-Shempp, D.E. Cutlip, P.G. Steg, S.L. Normand, E. Braunwald, S.D. Wiviott, D.J. Cohen, D.R. Holmes Jr., M.W. Krucoff, J. Hermiller, H.L. Dauerman, D.I. Simon, D.E. Kandzari, K.N. Garratt, D.P. Lee, T.K. Pow, P. Ver Lee, M.J. Rinaldi, J.M. Massaro, and DAPT Study Investigators Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents N. Engl. J. Med. 371 2014 2155 2166
15. V.L. Serebruany, V. Cherepanov, E. Golukhova, and M.H. Kim DAPT Trial after FDA update: Non cardiovascular deaths, cancer, and optimal treatment duration Cardiology 132 2015 74 80
16. N. Kipshidze, E. Platonova, J.J. Dinicolantonio, W. Kuliczkowski, and V.L. Serebruany Excessive long-term platelet inhibition with prasugrel or ticagrelor and risk of infection: another hidden danger? Am. J. Ther. 2015 e22 e27
17. V.L. Serebruany, and S.D. Fortmann Underutilization of novel antiplatelet agents - myths, generics, and economics Thromb. Haemost. 112 2014 4 7
18. PEGASUS-TIMI 54 study of BRILINTA® meets primary endpoint in both 60mg and 90mg doses Available for download at http://www.astrazeneca.com/Media/Press-releases/Article/20150114 - PEGASUS-TIMI-54-study - BRILINTA-meets-primary-endpoint-in-60mg-and-90mg-doses (Assessed March 27, 2015)
19. V.L. Serebruany, and D. Atar Central adjudication of myocardial infarction in outcome-driven clinical trials - common patterns in TRITON, RECORD, and PLATO? Thromb. Haemost. 108 2012 412 414
20. F. Verheugt Outcomes of positive randomised controlled clinical trials: double-blind or double vision? Thromb. Haemost. 108 2012 410 411